Zosano Pharma Corp (OQ:ZSAN)

Jun 13, 2020 06:00 am ET
Zosano Pharma to showcase new post-hoc analyses of Qtrypta’s (M207) clinical trial data comparing key efficacy results from the pivotal study and the open-label long term safety study on the 2020 Amer
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that new post-hoc efficacy analyses of QtryptaTM, Zosano’s lead investigational product candidate for the acute treatment of migraine, will be...
Jun 11, 2020 04:05 pm ET
Zosano Pharma Announces Change to a Virtual Meeting Format for 2020 Annual Meeting of Stockholders
Zosano Pharma Corporation (Nasdaq:ZSAN) (the “Company” or “Zosano”), a clinical-stage biopharmaceutical company, today announced a change in the format of its Annual Meeting of Stockholders (“Annual Meeting”) from in-person to virtual-only. Due to...
May 14, 2020 05:05 pm ET
Zosano Pharma Reports First Quarter 2020 Financial Results and Provides Corporate Update
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2020, as well as recent business highlights. "This quarter was marked by a momentous...
May 01, 2020 04:35 pm ET
Zosano Pharma Announces the Appointment of Christine Matthews as Chief Financial Officer
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the appointment of Christine Matthews as the company’s chief financial officer (CFO). Ms. Matthews, who previously served as interim CFO, will be...
Mar 13, 2020 08:00 am ET
Zosano Pharma Reports Fourth Quarter and Fiscal Year 2019 Financial Results
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and year ended December 31, 2019, as well as recent business highlights. “2019 was a transformational...
Mar 06, 2020 05:15 pm ET
Zosano Pharma Announces Closing of $11 Million Registered Direct Offering Priced At-the-Market
Zosano Pharma Corporation (Nasdaq:ZSAN) (“Zosano”), a clinical-stage biopharmaceutical company, today announced that it has closed its previously-announced registered direct offering priced at-the-market under Nasdaq rules of 11,903,506 shares of...
Mar 05, 2020 08:00 am ET
Zosano Pharma Announces $11 Million Registered Direct Offering Priced At-the-Market
Zosano Pharma Corporation (Nasdaq:ZSAN) (“Zosano”), a clinical-stage biopharmaceutical company, today announced that it has entered into definitive agreements with institutional investors for the issuance and sale in a registered direct offering of...
Mar 04, 2020 08:00 am ET
Zosano Pharma Announces FDA Acceptance of 505(b)(2) New Drug Application for Qtrypta™ for the Acute Treatment of Migraine
Zosano Pharma Corporation (Nasdaq: ZSAN), a biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) for Qtrypta™ for filing and substantive review. The...
Feb 12, 2020 08:20 am ET
Zosano Pharma Announces Pricing of $8.0 Million Public Offering of Common Stock and Warrants
Zosano Pharma Corporation (Nasdaq:ZSAN)  (the “Company” or “Zosano”), a clinical-stage biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of (i) 10,146,154 Class A Units, each consisting...
Feb 11, 2020 04:35 pm ET
Zosano Pharma Announces Proposed Public Offering of Common Stock and Warrants
Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced that it is commencing an underwritten public offering of units consisting of shares of common stock and warrants to purchase common stock. All of...
Dec 23, 2019 08:00 am ET
Zosano Announces FDA Submission of New Drug Application for Qtrypta
Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced the submission of a 505(b)(2) New Drug Application (“NDA”) for Qtrypta™ to the U.S. Food and Drug Administration (“FDA”) for the acute treatment of...
Nov 27, 2019 09:29 am ET
Zosano Announces Pricing of Registered Direct Offering
Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced that it has entered into a securities purchase agreement with several institutional investors providing for the issuance and sale of an aggregate...
Nov 14, 2019 04:05 pm ET
Zosano Pharma Reports Third Quarter 2019 Financial Results and Provides Corporate Update
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the third quarter ended September 30, 2019, as well as recent business highlights. "These next twelve months will be...
Nov 13, 2019 04:30 pm ET
Zosano Pharma Announces Completion of Pre-NDA Meetings with FDA for Qtrypta™
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it has received minutes from pre- New Drug Application (“NDA”) meetings with the Food and Drug Administration (“FDA”) for the acute treatment...
Nov 07, 2019 09:00 am ET
Zosano Pharma to Host Conference Call on Third Quarter 2019 Financial Results and Provide Operational Update
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and webcast on Thursday, November 14, 2019 at 4:30 p.m. ET to discuss results for the third quarter of 2019 and...
Oct 24, 2019 09:00 am ET
Zosano Pharma Initiates Phase 2/3 Clinical Study in Cluster Headache
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that the company has begun enrolling cluster headache patients in the ATAC clinical trial. This Phase 2/3 study will evaluate the efficacy of C213...
Oct 23, 2019 04:05 pm ET
Zosano Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that the Board of Directors granted a stock option to purchase 450,000 shares of Zosano’s common stock to Steven Lo in connection with his...
Oct 08, 2019 09:00 am ET
Zosano Pharma Announces CEO Transition
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that Steven Lo, veteran biotechnology and pharmaceutical executive, will become president and chief executive officer of Zosano effective October...
Sep 27, 2019 04:05 pm ET
Zosano Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that the Board of Directors granted a stock option to purchase 100,000 shares of Zosano’s common stock to a new employee as an inducement award....
Sep 26, 2019 09:00 am ET
Zosano Pharma to Present at the Cantor Global Healthcare Conference
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its chairman, president and chief executive officer, John Walker, will present a company overview at the 2019 Cantor Global Healthcare...
Sep 18, 2019 08:30 am ET
Zosano Pharma Announces the Appointment of Dushyant Pathak, Ph.D., as Senior Vice President of Business Development
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the appointment of Dushyant Pathak, Ph.D., as senior vice president of business development. “We are pleased to welcome Dushyant, who brings over...
Sep 09, 2019 08:30 am ET
Zosano Pharma Announces the Presentation of Multiple Positive Datasets from the Qtrypta™ Long-Term Safety Study at the Congress of the International Headache Society
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced an oral presentation and two poster presentations of positive data from a one-year long-term safety study of Qtrypta™ for the acute treatment of...
Sep 03, 2019 09:00 am ET
Zosano Pharma to Present at the H.C. Wainwright Annual Global Investment Conference
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its chairman, president and chief executive officer, John Walker, will present a company overview at the H.C. Wainwright 21st Annual Global...
Aug 23, 2019 09:00 am ET
Zosano Pharma Announces Upcoming Oral and Poster Presentations at the Congress of the International Headache Society
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that the company will deliver an oral presentation and two poster presentations at the 19th Congress of the International Headache Society (IHC)....
Aug 14, 2019 04:05 pm ET
Zosano Pharma Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2019, as well as recent business highlights. "We have concentrated our efforts on...
Aug 14, 2019 09:00 am ET
Zosano Pharma Files IND to Initiate a Phase 2/3 Clinical Study in Cluster Headache
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that the Company has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate a Phase 2/3...
Aug 07, 2019 04:05 pm ET
Zosano Pharma to Host Conference Call on Second Quarter 2019 Financial Results and Provide Operational Update
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and webcast on Wednesday, August 14, 2019 at 4:30 p.m. ET to discuss results for the second quarter of 2019 and...
Jul 15, 2019 06:00 am ET
Zosano Pharma Presents Migraine-ACT Scores for Qtrypta™ at the American Headache Society (AHS) Annual Scientific Meeting
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the presentation of Migraine-ACT scores for Qtrypta™ therapy used over 6-12 months. The Migraine Assessment of Current Therapy (or Migraine-ACT)...
Jul 03, 2019 08:30 am ET
Zosano Pharma Announces Keynote Speech at the Pharmaceutics & Advanced Drug Delivery Systems Conference
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that Hayley Lewis, senior vice president of operations at Zosano Pharma, will be presenting a keynote speech entitled, “A Novel Intracutaneous...
Jul 01, 2019 04:05 pm ET
Zosano Pharma Announces Upcoming Presentation at American Headache Society Annual Meeting
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that a poster and e-poster describing Migraine-ACT scores, or measures of patient satisfaction with the management of their migraines, following...
Jun 18, 2019 06:00 am ET
Zosano Pharma Completes Site Qualification Batches at Contract Manufacturing Organization as it Prepares for NDA Submission of Qtrypta™
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it has completed manufacturing of site qualification batches at its commercial manufacturing site for Qtrypta, the company’s investigational...
May 14, 2019 04:05 pm ET
Zosano Pharma Reports First Quarter 2019 Financial Results
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2019, as well as recent business highlights. "With a number of key catalysts planned in...
May 09, 2019 09:00 am ET
Zosano Announces Full Exercise of Underwriter’s Option to Purchase Additional Shares
Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced that it has issued and sold an additional 750,000 shares of common stock, pursuant to the exercise in full of the underwriter’s option to purchase...
May 08, 2019 04:30 pm ET
Zosano Pharma to Host Conference Call on First Quarter 2019 Financial Results and Provide Operational Update
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and webcast on Tuesday, May 14, 2019 at 4:30 p.m. ET to discuss results for the first quarter of 2019 and...
Apr 16, 2019 08:30 am ET
Zosano Announces the Publication of an Analysis of Acute Treatments for Migraine in Headache: The Journal of Head and Face Pain
Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, today announced the peer-reviewed publication of a review and analysis of recently-completed trials using newly FDA-recommended...
Apr 16, 2019 07:30 am ET
New Research Coverage Highlights Franklin Resources, Corporate Office Properties Trust, Guidewire Software, Bemis, T2 Biosystems, and Zosano Pharma — Consolidated Revenues, Company Growth, and Expecta
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Franklin Resources, Inc. (NYSE:BEN), Corporate Office Properties Trust...
Apr 09, 2019 09:00 am ET
Zosano Announces Pricing of Public Offering of Common Stock
Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of its common stock for gross proceeds of $17.5 million, before deducting underwriting discounts and...
Apr 08, 2019 04:01 pm ET
Zosano Pharma Announces Proposed Public Offering of Common Stock
Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares to be sold in the offering will be offered...
Mar 14, 2019 04:05 pm ET
Zosano Pharma Reports Fourth Quarter and Fiscal Year 2018 Financial Results
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and year ended December 31, 2018, as well as recent business highlights.
Mar 11, 2019 04:30 pm ET
Zosano Pharma Announces Presentation and Participation at the 31st Annual Roth Conference
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its chairman, president and chief executive officer, John Walker, will participate in a panel titled “Drug Delivery” to be held on Monday,...
Mar 07, 2019 04:30 pm ET
Zosano Pharma to Host Conference Call on Fourth Quarter and Full Year 2018 Financial Results and Provide Operational and Strategic Update
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and webcast on Thursday, March 14, 2019 at 4:30 p.m. ET to discuss financial results for the fourth quarter and...
Feb 25, 2019 07:45 am ET
Detailed Research: Economic Perspectives on Zosano Pharma, Appian, Ross Stores, Alleghany, ZAGG, and Lindsay — What Drives Growth in Today's Competitive Landscape
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Zosano Pharma Corporation (NASDAQ:ZSAN), Appian Corporation (NASDAQ:APPN),...
Feb 22, 2019 08:31 am ET
Thinking about buying stock in Apple, Canopy Growth Corp, Immune Design, Roku Inc or Zosano Pharma?
NEW YORK, Feb. 22, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAPL, CGC, IMDZ, ROKU, and ZSAN....
Feb 21, 2019 06:00 am ET
Zosano Announces Completion of the Final Milestone in the Long-Term Safety Study of Qtrypta™ for the Acute Treatment of Migraine Disease
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the completion of the second and final goal of the long-term safety study for Qtrypta, in which patients treated migraine attacks over a one year...
Jan 31, 2019 08:30 am ET
Zosano Announces Publication of Positive Data on Qtrypta’s™ Potential as an Acute Treatment for Patients with Difficult-to-Treat Migraines
Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, today announced the peer-reviewed publication of a post-hoc analysis of its pivotal Phase 2/3 (ZOTRIP) study in Headache: The Journal...
Jan 16, 2019 08:30 am ET
Zosano Appoints Linda Grais M.D., J.D. to Board of Directors
Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, today announced the appointment of Linda Grais, M.D., J.D. to its board of directors. Dr. Grais brings a diverse and important set of...
Dec 12, 2018 08:30 am ET
Zosano Receives Conditional FDA Acceptance of Proposed Brand Name Qtrypta™ for M207
Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has conditionally accepted the proposed brand name Qtrypta™ for M207,...
Nov 14, 2018 04:05 pm ET
Zosano Pharma Reports Third Quarter 2018 Financial Results and Operational Update
Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, today announced financial results for the third quarter ended September 30, 2018. “The Company has continued to execute upon our...
Nov 07, 2018 04:30 pm ET
Zosano Pharma to Host Conference Call on Third Quarter 2018 Financial Results and Provide Operational Update
Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and webcast to be held on Wednesday, November 14, 2018 at 4:30PM ET. At this time,...
Oct 25, 2018 09:15 am ET
Recent Analysis Shows Stellus Capital Investment, Nuance Communications, ProPetro Holding, Sanchez Energy, Granite Point Mortgage Trust, and Zosano Pharma Market Influences — Renewed Outlook, Key Driv
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Stellus Capital Investment Corporation (NYSE:SCM), Nuance...
Oct 23, 2018 08:30 am ET
Zosano Treats over 4,000 Migraines and Reaches an Important Goal in M207-ADAM Long-term Safety Study  
Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, today announced that more than 150 evaluable subjects have completed their six month visit in the M207-ADAM study (the "Study"), a...
Oct 18, 2018 08:00 am ET
Zosano Pharma to Host Key Opinion Leader Meeting on New Treatments for Migraine and the Migraine Patients’ Perspective
Zosano Pharma Corporation (Nasdaq: ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company developing and commercializing therapies that deliver rapid systemic absorption by leveraging its novel and proprietary technology,...
Oct 16, 2018 08:30 am ET
Zosano Appoints New Chief Financial Officer
Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company developing and commercializing therapies that deliver rapid systemic absorption by leveraging its novel and proprietary technology,...
Oct 03, 2018 08:30 am ET
Zosano Pharma Engages Contract Manufacturer as Part of the Commercialization Strategy for M207
Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company developing and commercializing therapies that deliver rapid systemic absorption by leveraging its novel and proprietary technology,...
Sep 26, 2018 08:30 am ET
Zosano Pharma Enters Into Capital Equipment Lease Agreement With Trinity Capital Investment
Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company developing and commercializing therapies that deliver rapid systemic absorption by leveraging its novel and proprietary technology,...
Sep 19, 2018 08:30 am ET
Zosano Pharma Completes Manufacture of M207 Registration Batches
Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using its proprietary Adhesive Dermally-Applied...
Sep 06, 2018 08:30 am ET
Zosano Pharma to Present Phase 3 Safety Study Update for ADAM™ Technology in the Delivery of Zolmitriptan at the 5th Annual Transdermal & Intradermal Drug Delivery Systems Conference
Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, developing and commercializing therapies that deliver rapid systemic absorption by leveraging its novel and proprietary...
Sep 05, 2018 08:30 am ET
Zosano Pharma and Collaborators to Present Efficacy Data for M207 in the Treatment of Migraine at the 17th Biennial Migraine Trust International Symposium (MTIS)
Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using its proprietary Adhesive Dermally-Applied...
Aug 09, 2018 04:00 pm ET
Zosano Pharma Reports Second Quarter 2018 Financial Results and Operational Update
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, developing and commercializing therapies that deliver rapid systemic absorption by leveraging its novel and proprietary technology called Adhesive Dermally-Applied...
Aug 02, 2018 08:30 am ET
Zosano Pharma to Host Conference Call on Second Quarter 2018 Financial Results and Provide Operational Update
Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”) a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using its proprietary Adhesive Dermally-Applied Microarray...
Jul 17, 2018 08:30 am ET
Zosano Announces Positive Data from a Nonclinical Evaluation of Pharmacokinetics and Skin Tolerability Study for ADAM™ Technology for the Delivery of Zolmitriptan
Zosano Pharma (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies that deliver rapid systemic absorption using a novel and proprietary technology called Adhesive Dermally-Applied...
Jun 27, 2018 02:00 pm ET
Zosano to Present Additional Analyses from the ZOTRIP Pivotal Study on Pain Relief and Recurrence at the 2018 American Headache Society (AHS) Meeting
Zosano Pharma, a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies that deliver rapid systemic absorption using a novel and proprietary technology called Adhesive Dermally-Applied Microarray...
Jun 20, 2018 08:30 am ET
Zosano Announces Publication on Adhesive Dermally-Applied Microarray (ADAM™) Technology for the Delivery of Zolmitriptan in Migraine in Journal of Pharmaceutics
Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to subjects using its proprietary Adhesive Dermally-Applied...
May 31, 2018 08:20 am ET
Market Trends Toward New Normal in ANSYS, Pearson, Qualys, H. B. Fuller, Cabot Microelectronics, and Zosano Pharma — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ANSYS, Inc. (NASDAQ:ANSS), Pearson, PLC (NYSE:PSO), Qualys, Inc....
May 23, 2018 08:30 am ET
Zosano Announces Publication of Most Bothersome Symptom Data from the ZOTRIP Pivotal Study in Headache: The Journal of Head and Face Pain
Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to subjects using its proprietary Adhesive Dermally-Applied...
May 22, 2018 08:30 am ET
Zosano Appoints Steven A. Elms to Board of Directors
Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”) a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to subjects using its proprietary Adhesive Dermally-Applied Microarray...
May 15, 2018 04:00 pm ET
Zosano Pharma Reports First Quarter 2018 Financial Results and Operational Update
Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”) a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using its proprietary Adhesive Dermally-Applied Microarray...
May 14, 2018 08:30 am ET
Zosano Reaches Another Enrollment Milestone in M207-ADAM Long-term Safety Study
Zosano Pharma Corp. (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to subjects using its proprietary Adhesive Dermally-Applied Microarray...
May 08, 2018 04:05 pm ET
Zosano Pharma to Host Conference Call on First Quarter 2018 Financial Results and Provide Operational Update
Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”) a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using its proprietary Adhesive Dermally-Applied Microarray...
Apr 05, 2018 08:15 am ET
Analysis: Positioning to Benefit within Euronet Worldwide, Innospec, Zosano Pharma, Ardelyx, Crown Castle International, and Aldeyra Therapeutics — Research Highlights Growth, Revenue, and Consolidate
NEW YORK, April 05, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Euronet Worldwide, Inc. (NASDAQ:EEFT), Innospec Inc....
Apr 03, 2018 04:05 pm ET
Zosano Announces Closing of Public Offering of Common Stock
FREMONT, Calif., April 03, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using its proprietary ADAM technology, today announced the closing of the previously...
Apr 02, 2018 12:56 pm ET
Zosano Pharma to Host Conference Call to Provide Operational Update
FREMONT, Calif., April 02, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical stage biopharmaceutical company focused on providing systemic administration of therapeutics to patients using our proprietary Adhesive Dermally-Applied Microarray (ADAM) technology, today announced that it...
Mar 29, 2018 09:00 am ET
Zosano Announces Pricing of Public Offering of Common Stock
FREMONT, Calif., March 29, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using its proprietary ADAM technology, today announced the pricing of an underwritten...
Mar 16, 2018 08:30 am ET
Mar 12, 2018 08:45 am ET
Zosano Pharma Reports Fourth Quarter and Fiscal Year 2017 Financial Results and Operational Update
FREMONT, Calif., March 12, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”) a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using its proprietary Adhesive Dermally-Applied Microarray (“ADAM™”), today...
Mar 08, 2018 07:30 am ET
Report: Developing Opportunities within Owens & Minor, Zosano Pharma, Organovo, Summit Materials, Ralph Lauren, and Clearside Biomedical — Future Expectations, Projections Moving into 2018
NEW YORK, March 08, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Owens & Minor, Inc. (NYSE:OMI), Zosano...
Mar 02, 2018 08:30 am ET
Jan 25, 2018 09:00 am ET
Zosano Announces Results of Special Meeting of Stockholders and 1-for-20 Reverse Stock Split
Shares of Common Stock Will Begin Trading on Split-Adjusted Basis on January 26, 2018
Dec 15, 2017 04:30 pm ET
Zosano Announces Resignation of Bruce Steel from Board of Directors
FREMONT, Calif., Dec. 15, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”) a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using our proprietary ADAM technology, announced today that...
Nov 15, 2017 09:00 am ET
Zosano Pharma to Present at 29th Annual Piper Jaffray Healthcare Conference
FREMONT, Calif., Nov. 15, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corp. (NASDAQ:ZSAN) (“Zosano” or the “Company”) a clinical stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to subjects using its proprietary Adhesive Dermally-Applied Microarray (“ADAM”)...
Nov 09, 2017 04:05 pm ET
Zosano Pharma Reports Third Quarter 2017 Financial Results and Operational Update
FREMONT, Calif., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) a clinical stage biopharmaceutical company focused on providing systemic administration of therapeutics to patients using our proprietary Adhesive Dermally-Applied Microarray (ADAM) technology, today announced financial results...
Nov 08, 2017 08:30 am ET
Zosano Pharma Announces Initiation of Long-Term Safety Study for M207 as an Acute Treatment of Migraine
FREMONT, Calif., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corp. (NASDAQ:ZSAN) (“Zosano” or the “Company”) a clinical stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to subjects using its proprietary Adhesive Dermally-Applied Microarray (“ADAM”)...
Oct 20, 2017 04:15 pm ET
Zosano Enters into Common Stock Purchase Agreement with Lincoln Park Capital
FREMONT, Calif., Oct. 20, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”) a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using our proprietary ADAM technology, announced today that it has entered into a common stock purchase agreement with Lincoln Park Capital Fund, LLC (“LPC”), a Chicago-based institutional investor, for up to $35 million. ...
Oct 12, 2017 02:42 pm ET
Zosano Announces Publication of Pivotal Data of ADAM Zolmitriptan for the Acute Treatment of Migraine in Cephalalgia
FREMONT, Calif., Oct. 12, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corp. (NASDAQ:ZSAN) (“Zosano” or the “Company”) a clinical stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to subjects using its proprietary Adhesive Dermally-Applied Microarray (“ADAM”) technology, announced today that Cephalalgia had published the Company’s positive results from our pivotal, multi-center, double blind, placebo controlled, trial demonstrating efficacy and safety of M207, our formulation of zolmitriptan using our ADAM technology....
Sep 26, 2017 05:02 pm ET
Zosano Provides Patent Application Update
FREMONT, Calif., Sept. 26, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”) a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using our proprietary ADAM technology, received official written notification of an Office action from the U.S. Patent and Trademark Office (USPTO) today regarding our patent application 15/438,455 “Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines.”    ...
Aug 10, 2017 04:01 pm ET
Zosano Pharma Reports Second Quarter 2017 Financial Results and Operational Update
John Walker appointed permanent CEO at Zosano FREMONT, Calif., Aug. 10, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical stage biopharmaceutical company focused on providing systemic administration of therapeutics to patients using our proprietary Adhesive Dermally-Applied Microarray (ADAM) technology, today announced financial results for the second quarter ended June 30, 2017. In addition, the Company’s Board of Directors has appointed John Walker, Zosano’s current Chairman and Interim CEO, as the permanent CEO, effective immediately.  Mr. Walker will also rema...
Jun 14, 2017 04:01 pm ET
Zosano Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
FREMONT, Calif., June 14, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using our proprietary ADAM technology, today announced that it has approved inducement option grants to two new employees to purchase an aggregate of 100,000 shares of the Company’s common stock with an exercise price of $1.35 per share, which was the closing price on June 13, 2017. Each stock option has a ten-year term and vests over four years, with one-fourth vesting on the fi...
May 09, 2017 04:00 pm ET
Zosano Reports First Quarter 2017 Financial Results and Announces Management Changes
Pivotal trial of M207 meets co-primary endpoints to establish fast and durable pain relief$29.3 million follow-on offering of common stock provides funding for initiating required safety study and meeting pre-commercialization CMC/ manufacturing criteriaZosano names John P. Walker Interim CEO FREMONT, Calif., May 09, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a CNS-focused company with a lead product, M207, that recently established a differentiated safety and efficacy profile in a pivotal trial as an acute treatment for migraine, today reported financial results for ...
Mar 22, 2017 04:01 pm ET
Zosano Announces Closing of Public Offering of Common Stock and Exercise of Underwriters’ Over-Allotment Option
FREMONT, Calif., March 22, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), an emerging CNS company focusing on developing an acute migraine treatment with a differentiated efficacy profile using the Company’s proprietary transdermal delivery system, today announced the closing of the previously announced public offering of 19,550,000 shares of its common stock at a price of $1.50 per share, which includes the exercise in full by the underwriters of their over-allotment option to purchase up to 2,550,000 additional shares of common stock....
Mar 01, 2017 07:00 am ET
Zosano Pharma Reports Fourth Quarter and Fiscal 2016 Financial Results and Business Update
FREMONT, Calif., March 01, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), an emerging central nervous system company focused on providing symptom relief to patients using the Company's proprietary intracutaneous delivery system, today announced financial results for the fourth quarter and year ended December 31, 2016....
Jan 23, 2017 05:17 pm ET
Zosano Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
FREMONT, Calif., Jan. 23, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), an emerging CNS company focusing on providing rapid symptom relief to patients using the Company’s proprietary transdermal delivery system, today announced that it has approved an inducement grant of options to purchase 35,000 shares of the Company’s common stock with an exercise price of $1.14 per share, the closing price on January 19, 2017, to a new employee. The stock options have a ten year term and vest over four years, with one-fourth vesting on the first anniversary of the date of grant and ...
Jan 05, 2017 08:30 am ET
Zosano Pharma Announces Last Subject Treated in its Migraine Pivotal Trial
FREMONT, Calif., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), an emerging CNS company focused on providing rapid symptom relief to patients using the Company's proprietary intracutaneous delivery system, today announced that the last subject has been treated in the Company’s registration-enabling, pivotal efficacy trial (the Zotrip trial), of M207 for the treatment of migraine....
Nov 22, 2016 05:00 pm ET
Zosano Pharma Announces Sale of Non-Strategic Asset
FREMONT, Calif., Nov. 22, 2016 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), an emerging central nervous system company focused on providing rapid symptom relief to patients using the Company’s proprietary intracutaneous delivery system, today announced that it has sold all of its interest in Zosano, Inc. for an aggregate cash purchase price of $225,000.  Zosano Pharma Corporation acquired 99.9% of the issued and outstanding common stock of Eco Planet Corp. (which was subsequently renamed Zosano, Inc.) in October 2013.   Zosano, Inc. is a shell company with no operations and...
Nov 09, 2016 04:20 pm ET
Zosano Pharma Reports Third Quarter 2016 Financial Results
FREMONT, Calif., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), an emerging central nervous system company focused on providing rapid symptom relief to patients using the Company's proprietary intracutaneous delivery system, today announced financial results for the third quarter ended September 30, 2016....
Sep 09, 2016 05:00 pm ET
Zosano Announces Inducement Grant for Georgia Erbez, Chief Business Officer
FREMONT, Calif., Sept. 09, 2016 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), an emerging CNS company focusing on providing rapid symptom relief to patients using the Company’s proprietary transdermal delivery system, today announced that it has approved an inducement grant of options to purchase 252,000 shares of the Company’s common stock with an exercise price of $0.77 per share, the closing price on September 7, 2016, to Georgia Erbez, the Company's recently hired Chief Business Officer. The stock options have a ten year term and vest over four years, with one-fourth vesti...
Sep 08, 2016 08:30 am ET
Zosano Appoints Georgia Erbez as Chief Business Officer
FREMONT, Calif., Sept. 08, 2016 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), an emerging CNS company focusing on providing rapid symptom relief to patients using the Company’s proprietary transdermal delivery system, today announced the appointment of Ms. Georgia Erbez as its Chief Business Officer, effective September 8, 2016. Ms. Erbez will continue to serve as Zosano’s Interim Chief Financial Officer....
Aug 31, 2016 03:28 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Shareholders of Zosano Pharma Corporation - ZSAN
NEW YORK, Aug. 31, 2016 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zosano Pharma Corporation ("Zosano" or the "Company") (NASDAQ: ZSAN).  Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980....
Aug 16, 2016 08:39 am ET
Zosano Pharma Announces Pricing of Private Placement of Common Stock and Warrants
FREMONT, Calif., Aug. 16, 2016 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a CNS company focused on providing rapid symptom relief to patients using the Company’s proprietary intracutaneous delivery system, today announced that it has entered into a securities purchase agreement to sell shares of its common stock and warrants to purchase shares of its common stock at a price of $1.57 per unit in a private placement.  This financing will generate aggregate gross proceeds at closing of approximately $7.5 million from the sale of the units, before deducting placement agent fe...
Aug 10, 2016 04:15 pm ET
Zosano Pharma Reports Second Quarter 2016 Financial Results
FREMONT, Calif., Aug. 10, 2016 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), an emerging CNS company focused on providing rapid symptom relief to patients using the Company's proprietary intracutaneous delivery system, today announced financial results for the second quarter ended June 30, 2016....
Jul 25, 2016 08:30 am ET
First Subject Treated in Zosano Pharma’s Pivotal Efficacy Trial for M207 Patch for Acute Migraine
FREMONT, Calif., July 25, 2016 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), an emerging CNS company focusing on providing rapid symptom relief to patients using the Company’s proprietary transdermal delivery system, today announced the dosing of its first subject in its registration-enabling pivotal efficacy trial (the Zotrip trial), of its M207 patch, formerly known as ZP-Triptan, for the treatment of acute migraine. ...
Jun 17, 2016 08:30 am ET
Zosano Pharma Enrolls First Subject in Pivotal Clinical Trial for ZP-Triptan Patch Program for Treatment of Migraine
FREMONT, Calif., June 17, 2016 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical stage specialty pharmaceutical company with proprietary technology for the dermal delivery of drugs, today announced the enrollment of its first subject in a pivotal efficacy trial of its ZP-Triptan patch treatment for acute migraine. ZP-Triptan is a proprietary zolmitriptan-coated microneedle patch that is applied to a subject’s upper arm to deliver zolmitriptan during a migraine attack....
May 17, 2016 12:58 pm ET
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Zosano Pharma Corporation (ZSAN)
NEW YORK, May 17, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Zosano Pharma Corporation ("Zosano" or the "Company") (NASDAQ: ZSAN). Such investors are advised to contact Peretz Bronstein or his investor relations analyst Yael Hurwitz at info@bgandg.com or 212-697-6484. ...
May 12, 2016 04:05 pm ET
Zosano Pharma Reports First Quarter 2016 Financial Results
FREMONT, Calif., May 12, 2016 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical stage specialty pharmaceutical company with proprietary technology for the dermal delivery of drugs, today announced financial results for the first quarter ended March 31, 2016....
May 09, 2016 08:30 am ET
Zosano Announces Appointment of John P. Walker as Chairman of the Board
FREMONT, Calif., May 09, 2016 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical stage specialty pharmaceutical company with proprietary technology for the dermal delivery of drugs, announced today that it named Mr. John P. Walker Chairman of the Board....
May 02, 2016 04:05 pm ET
Zosano Pharma to Report First Quarter 2016 Financial Results
FREMONT, Calif., May 02, 2016 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) today announced that it plans to report financial results for the first quarter of 2016 on Thursday, May 12, 2016. Zosano will host a conference call and webcast to provide an update at 4:30 pm ET (1:30 pm PT) that day. The call will be hosted by Konstantinos Alataris, Ph.D., President and CEO, and Winnie W. Tso, CFO....
Apr 15, 2016 12:13 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Shareholders of Zosano Pharma Corporation - ZSAN
NEW YORK, April 15, 2016 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zosano Pharma Corporation ("Zosano" or the "Company") (NASDAQ: ZSAN). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980....
Apr 14, 2016 11:51 am ET
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Zosano Pharma Corporation (ZSAN)
NEW YORK, April 14, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Zosano Pharma Corporation ("Zosano" or the "Company") (NASDAQ: ZSAN). Such investors are advised to contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz at info@bgandg.com or 212-697-6484....
Apr 08, 2016 04:41 pm ET
ZOSANO NOTIFICATION: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Zosano Pharma Corporation To Contact The Firm
NEW YORK, April 8, 2016 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Zosano Pharma Corporation ("Zosano" or the "Company") (NASDAQ:ZSAN)....
Feb 09, 2016 03:39 pm ET
INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Violations of Federal Securities Laws by the Board of Zosano Pharma Corporation -- ZSAN
NEW YORK, Feb. 9, 2016 /PRNewswire/ -- Levi & Korsinsky announces it has commenced an investigation of Zosano Pharma Corporation (NASDAQCM: ZSAN) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.  ...
Jan 21, 2016 01:14 pm ET
Harwood Feffer LLP Announces Investigation of Zosano Pharma Corporation
NEW YORK, Jan. 21, 2016 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of Zosano Pharma Corporation ("Zosano" or the "Company") (NASDAQ: ZSAN), concerning whether the board has breached its fiduciary duties to shareholders....